GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Dividend-Payout-to-FFO

Pharos IBio Co (XKRX:388870) Dividend-Payout-to-FFO


View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Pharos IBio Co Business Description

Traded in Other Exchanges
N/A
Address
427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.